In addition, with more emerging evidence for the benefit of ACE inhibitor/angiotensin II receptor blockers, β-blockers and aldosterone antagonists in HF patients with EF between 40% and 49%,20 healthcare providers should be educated about these updates. Here, ACE is linked to hydrops fetalis.